Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27590195 | 0.83 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2KDM4EKMT2AMEN1 | |
| SCHEMBL26212901 | 0.81 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL12459545 | 0.81 | ALDH1A1 (0.65) | ALDH1A1SMN1; SMN2KDM4EKMT2AMEN1 | |
| SCHEMBL12459533 | 0.81 | ALDH1A1 (0.67) | ALDH1A1SMN1; SMN2KDM4EPOLBKMT2A | |
| SCHEMBL26212905 | 0.80 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2KDM4ELMNAHTT | |
| SCHEMBL13572985 | 0.78 | ALDH1A1 (0.69) | ALDH1A1SMN1; SMN2KDM4EPOLBKMT2A | |
| SCHEMBL1504601 | 0.78 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL26212925 | 0.77 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2KDM4EKMT2AMEN1 | |
| SCHEMBL26212922 | 0.76 | ALDH1A1 (0.51) | ALDH1A1SMN1; SMN2KDM4EPOLBKMT2A | |
| SCHEMBL7023027 | 0.75 | TSHR (0.64) | ALDH1A1KDM4EKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115843271-B | Indole derivatives and their use for the treatment of cancer | 克洛德贝纳尔-里昂第一大学 | 2024-08-13 | — | — | CN | disclosed |
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2023-09-07 | — | — | US | disclosed |
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | UNIVERSITE CLAUDE BERNARD LYON 1 (FR) | 2023-09-07 | — | — | US | disclosed |
| CN-115843271-A | Indole derivatives and their use for the treatment of cancer | 克洛德贝纳尔-里昂第一大学 | 2023-03-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278983-A1 | INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER | CSNK2A1, IDO1, CSNK2A3 | ALDH1A1 995/4885SMN1; SMN2 4836/4885KDM4E 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.